Sensitization of lidocaine on hepatoma H22-bearing mice treated by mitomycin

Objective To observe the sensitization of lidocaine on subcutaneous hepatoma H22-bearing mice and abdominal cavity H22 tumor-bearing mice treated by mitomycin. Methods According to the random number table method, the mice were divided into subcutaneous tumor-bearing group and abdominal cavity tumor-bearing group, with 15 mice in each group. The mice in the two groups were further divided into three subgroups: model group, mitomycin group, mitomycin + lidocaine group, with 5 mice in each subgroup. The day before the intraperitoneal injection, the density of H22 cells obtained from peritoneal culture of one mouse was adjusted to 5×106/ml. Subcutaneous tumor-bearing group mice were injected H22 cells into the right armpit, and abdominal cavity tumor-bearing group mice were injected H22 cells into the abdominal cavity, 0.2 ml per mouse. Intraperitoneal injection was given after inoculation for 24 h (the experiment day 1), followed by intraperitoneal injection on day 5 and 9. Univariate ANOVA analysis and t test were used to analyze the solid tumor weight and tumor inhibition rate on the 11th day of subcutaneous tumor-bearing mice, and the survival time and life extension rate within 60 days of abdominal cavity tumor-bearing mice. Results The solid tumor weight of subcutaneous tumor-bearing mice model group, mitomycin group and mitomycin + lidocaine group were (3.77±1.02) g, (1.67±0.28) g, (0.74±0.19) g, respectively, and the differences in the three groups were statistically different (F = 31.753, P < 0.01); compared with the subcutaneous model group, the subcutaneous solid tumor weights of mitomycin group and mitomycin + lidocaine group were decreased and the differences were both statistically different (t = 2.10, P < 0.01; t = 3.04, P < 0.01); the subcutaneous solid tumor weight of mitomycin + lidocaine group was lower than that of mitomycin group (t = 0.93, P = 0.034). The tumor inhibition rate of mitomycin group and mitomycin + lidocaine group reached 55.70% and 80.37% respectively. The survival time of abdominal cavity tumor-bearing mice in model group, mitomycin group and mitomycin + lidocaine group was (16.80±0.84) d, (28.80±6.30) d, (40.40±12.86) d, respectively, and the differences in the three groups were statistically different (F = 10.155, P = 0.003); compared with the abdominal cavity tumor-bearing mice model group, the survival time of mice in mitomycin group and mitomycin + lidocaine group was prolonged (t = 12.00, P = 0.041; t = 23.60, P = 0.001), and it was found that survival time in mitomycin + lidocaine group was longer than that in mitomycin group (t = 11.60, P = 0.047). The life extension rate of mitomycin group and mitomycin + lidocaine group reached 71.43% and 140.48% respectively. Conclusion Lidocaine can increase the sensitization of mitomycin on hepatoma H22-bearing mice. Key words: Liver neoplasms; Lidocaine; Mitomycin; Sensitivity effect; Mice; Disease models, animal; Cells, H22